Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

Inclusion Criteria

• •1. Patient able to understand the process of the informed consent form (ICF);
• •2. Male aged ≥18 years old;
• •3. Having a histologically confirmed diagnosis of prostate adenocarcinoma;
• •4. Having an indication of androgen deprivation treatment:
• •1. Being on treatment with monthly or quarterly goserelin acetate depot formulation for at least 3 months and for a maximum of 18 months OR;
• •2. Having an indication to start treatment with quarterly goserelin acetate depot formulation.
• •5. Patient with ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2;
• •6. Patient with appropriate castration level, defined by a serum testosterone level ≤50 ng/dL (≤1.73 nmol/L) demonstrated before V1.
• •7. Appropriate hematologic function in the screening period: neutrophil count \>1,500/μL, platelets \>100,000/μL, hemoglobin \>10 g/dL;
• •8. Appropriate liver function in the screening period of the study: total serum bilirubin ≤1.5 x upper normal limit, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) ≤40 U/L, alkaline phosphatase \<130 U/L, gamma-GT (glutamyl transferase) \<100 U/L;
• •9. Appropriate kidney function in the screening period of the study: serum urea within normal limits for the method used at the institution, serum creatinine between 0.6 and 1.3 mg/dL, creatinine clearance calculated by the Cockroft- Gault formula \> 40 mL/min;